KLRK1 and acute myeloid leukemia: Previously, a phase 1 clinical trial revealed no grade 3 or above adverse events related to NKG2D CAR T cell therapy in patients with relapsed/refractory AML [43], indicating that it is safe targeting NKG2DLs in AML patients.